On November 24, 2025 Sprint Bioscience AB (publ) reported the sale of its TREX1 cancer program to Gilead Sciences, Inc. The agreement includes an upfront payment of USD 14 million, as well as potential clinical, regulatory, and commercial milestone payments totaling up to USD 400 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to enter into this agreement with Gilead, whom we value highly as a business partner. We appreciate their forward-looking approach and strong commitment to cutting-edge pharmaceutical development. TREX1 has demonstrated significant potential in the pre-clinical phase, and our decision to sell the program, rather than license it, reflects a strategic shift toward more flexible, value-driven exit opportunities," said Johan Emilsson, CEO of Sprint Bioscience.

(Press release, Sprint Bioscience, NOV 24, 2025, View Source [SID1234660959])